Skip to content

Application of Different Priming Solutions for Prevention of Hypotension Associated with DPMAS Treatment

Application of Different Priming Solutions for Prevention of Hypotension Associated with DPMAS Treatment

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090058
Enrollment
Unknown
Registered
2024-09-23
Start date
2024-08-20
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute-on-chronic (subacute) liver failure

Interventions

Observation group A:Traditional priming method + succinylated gelatin injection 500ml priming the adsorption column.
Observation group B:Traditional priming method + succinylated gelatin injection 500ml priming the adsorption column + succinylated gelatin injection 500ml priming the circuit.
Control Group C:Traditional priming method

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Age = 18 and < 70 years old, gender unspecified; 2) Meets the diagnostic criteria of the "Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)"; 3) Patients determined by the physician to have indications for DPMAS+PE treatment; 4) Voluntarily participates in this clinical trial and signs the informed consent form; 5) Systolic blood pressure < 90mmHg with no symptoms related to hypotension.

Exclusion criteria

Exclusion criteria: 1) Patients with severe active bleeding or disseminated intravascular coagulation; 2) Patients with a severe allergic reaction to blood products or medications used during the treatment process, such as plasma, heparin, protamine, etc.; 3) Patients in an unstable phase of myocardial infarction or cerebral infarction; 4) Patients who have participated in other clinical trials within the past month; 5) Patients deemed unsuitable for inclusion by the researcher for other reasons; 6) Patients with a history of severe allergies; 7) Patients allergic to gelatin injection; 8) Patients with circulatory overload, fluid retention, severe renal failure, bleeding tendency, or pulmonary edema; 9) Patients using terlipressin and pressor medications.

Design outcomes

Primary

MeasureTime frame
Blood pressure;

Secondary

MeasureTime frame
heart rate;adverse reaction;

Countries

China

Contacts

Public ContactFang Chen

West China Hospital, Sichuan University

979566116@qq.com+86 189 8060 6933

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026